This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)

  • Clinicaltrials.gov identifier

    NCT04383574

  • Recruitment Status

    Active, not recruiting

  • First Posted

    May 12, 2020

  • Last update posted

    August 18, 2021

Study Description

Brief summary:

This study is a randomized, double-blinded, and placebo controlled phase 1&2 clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the safety and immunogenicity of the experimental vaccine in healthy elderly aged 60 years and above.

  • Condition or Disease:COVID-19
  • Intervention/Treatment: Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
    Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
    Biological: Two doses of placebo at the schedule of day 0,28
    Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
  • Phase: Phase 1/Phase 2

Detailed Description

This study is a randomized, double-blinded, single-center, placebo-controlled phase 1&2 clinical trial in healthy elderly aged 60 years and above. The experimental vaccine and placebo were both manufactured by Sinovac Research & Development Co., Ltd. A total of 422 subjects will be enrolled, with 72 in phase 1 and 350 in phase 2. 72 Subjects with 36 at medium dosage stage and 36 at high dosage stage in phase 1 will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and the subjects at each dosage stage will be assigned in a 2:1 ratio to receive investigational vaccine or placebo respectively.All enrolled subjects will receive 1 dose of booster immunization 1 year after primary immunization.350 Subjects in phase 2 will receive two doses of primary immunization according to the immunization schedule of day 0,28,the subjects will be assigned in a ratio of 2:2:2:1 to receive the low dosage, medium dosage, high dosage vaccine, or placebo. All enrolled subjects will received 1 dose of booster immunization 6 months after primary immunization.

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 422 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Prevention
  • Official Title: A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above
  • Actual Study Start Date: May 2020
  • Estimated Primary Completion Date: December 2021
  • Estimated Study Completion Date: July 2022

Arms and interventions

Arm Intervention/treatment
Experimental: Experimental Vaccine-medium dosage
24 participants at medium dosage stage in phase Ⅰ will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 100 participants at medium dosage stage in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd..Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
Experimental: Experimental Vaccine-high dosage
24 participants at high dosage stage in phase Ⅰ will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 100 participants at high dosage stage in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd..Two doses of high dosage (1200SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with medium dosage (1200SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
Placebo Comparator: Placebo
24 participants including 12 at medium dosage stage and 12 at high dosage in phase Ⅰ will receive two doses of placebo according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 50 participants in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
Biological: Two doses of placebo at the schedule of day 0,28
The placebo was manufactured by Sinovac Research & Development Co., Ltd., Two doses of placebo at the schedule of day 0,28,and one dose of booster immunization with placebo 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
Experimental: Experimental Vaccine-low dosage
100 participants at low dosage stage in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd..Two doses of low dosage (300SU/0.5ml)experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with low dosage (300SU/0.5ml) experimental vaccine 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.

Outcome Measures

  • Primary Outcome Measures: 1. Safety index-incidence of adverse reactions [ Time Frame: Day 0-28 after each dose vaccination ]
    Incidence of adverse reactions after each dose vaccination
  • 2. Immunogenicity index-seroconversion rates of neutralizing antibody [ Time Frame: 28 days after the second dose vaccination ]
    The seroconversion rate of neutralizing antibody 28 days after the second dose vaccination.
  • Secondary Outcome Measures: 1. Immunogenicity index-seroconversion rate, seropositive rate, GMT, and GMI in phase Ⅰ [ Time Frame: 28 days after the first dose vaccination in phase Ⅰ ]
    The seroconversion rate, seropositive rate, GMT, and GMI 28 days after the first dose vaccination in phase Ⅰ
  • 2. Safety index-incidence rate of adverse reactions [ Time Frame: within 7 days after each dose vaccination ]
    Incidence rate of adverse reactions within 7 days after each dose vaccination
  • 3. Safety index-incidence rate of serious adverse events in phase Ⅰ [ Time Frame: From the beginning of the vaccination to 6 months after the booster immunization ]
    Incidence rate of SAEs from the beginning of the vaccination to 6 months after the booster immunization in phase Ⅰ
  • 4. Safety index-incidence rate of serious adverse events in phase Ⅱ [ Time Frame: From the beginning of the vaccination to 12 months after the booster immunization vaccination ]
    Incidence rate of SAEs from the beginning of the vaccination to 12 months after the booster immunization vaccination in phase Ⅱ
  • 5. Immunogenicity index-seropositive rate, GMT, and GMI of neutralizing antibodies [ Time Frame: 28 days after the second dose vaccination ]
    The seropositive rate, GMT, and GMI of neutralizing antibodies 28 days after the second dose vaccination;
  • Other Outcome Measures: 1. Immunogenicity index -seropositive rate and GMT of neutralizing antibodies [ Time Frame: 6 months after the second dose vaccination ]
    The seropositive rate and GMT 6 months after the second dose vaccination
  • 2. Immunogenicity index -seropositive rate and GMT of neutralizing antibodies in phase Ⅰ [ Time Frame: 12 months after the second dose vaccination ]
    The seropositive rate and GMT 12 months after the second dose vaccination in phase Ⅰ
  • 3. Immunogenicity index -seropositive rate, GMT, and GMI of neutralizing antibodies [ Time Frame: 28 days after the booster vaccination ]
    The seropositive rate, GMT, and GMI 28 days after the booster vaccination in phase Ⅰ
  • 4. Immunogenicity index -seropositive rate, GMT of neutralizing antibodies in phase Ⅱ [ Time Frame: 7 days (or 14 days) and 28 days after the booster vaccination ]
    The seropositive rate, GMT, and GMI 7 days (or 14 days) and 28 days after the booster vaccination in phase Ⅱ
  • 5. Immunogenicity index -seropositive rate and GMT of neutralizing antibodies [ Time Frame: 6 months after the booster vaccination ]
    The seropositive rate and GMT 6 months after the booster vaccination
  • 6. Immunogenicity index -seropositive rate and GMT of neutralizing antibodies in phase Ⅱ [ Time Frame: 12 months after the booster vaccination ]
    The seropositive rate and GMT 12 months after the booster vaccination in phase Ⅱ

Eligibility Criteria

  • Ages Eligible for Study: 60 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria: - Healthy adults aged ≥60 years; - Be able to understand and sign the informed consent voluntarily; - Provide legal identification; Exclusion Criteria: - Travel / residence history of Wuhan city and surrounding areas or other communities with case reports within 14 days prior to the enrolment; - Contact with SARS-CoV-2 infected persons (positive for nucleic acid detection) within 14 days prior to the enrolment; - Contact patients with fever or respiratory symptoms from Wuhan city and surrounding areas, or from communities with case reports within 14 days prior to the enrolment; - Two or more cases of fever and / or respiratory symptoms in a small contact area of subjects, such as family, office, school class or other places within 14 days prior to the enrolment; - History of SARS; - History of SARS-CoV-2 infection; - History of asthma, allergy to vaccines or vaccine ingredients, and serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneuroedema; - Congenital malformation or developmental disorder, genetic defect, severe malnutrition, etc; - Autoimmune disease or immunodeficiency / immunosuppression; - Serious chronic disease, serious cardiovascular disease, hypertension and diabetes that cannot be controlled by drugs, hepatorenal disease, malignant tumor, etc; - Serious nervous system disease (epilepsy, convulsion or convulsion) or psychosis; - Thyroid disease or history of thyroidectomy, asplenia, functional asplenia, asplenia or splenectomy resulting from any condition; - Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; - Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute non-complicated dermatitis superficial corticosteroid therapy) in the past 6 months; - Long history of alcohol or drug abuse; - Receipt of blood products in the past 3 months; - Receipt of other investigational drugs in the past 30 days; - Receipt of attenuated live vaccines in the past 14 days; - Receipt of inactivated or subunit vaccines in the past 7 days; - Acute diseases or acute exacerbation of chronic diseases in the past 7 days; - Axillary temperature >37.0°C; - According to the investigator's judgment, the subject has any other factors that are not suitable for the clinical trial.

Contacts and Locations

Contacts

Locations

China, Hebei
Renqiu City Center for Disease Control and Prevention
Renqiu

Sponsors and Collaborators

Sinovac Research and Development Co., Ltd.

Investigators

Principal Investigator: Yuliang Zhao, Master Hubei Provincial Center for Disease Control and Prevention

More Information

  • Responsible Party: Sinovac Research and Development Co., Ltd.
  • ClinicalTrials.gov Identifier: NCT04383574 History of Changes
  • Other Study ID Numbers: PRO-nCOV-1002
  • First Posted: May 12, 2020 Key Record Dates
  • Last Update Posted: August 18, 2021
  • Last Verified: July 2021
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: COVID-19